tetano
Editor, Senior Moderator
Front Immunol
. 2023 Jul 7;14:1177324.
doi: 10.3389/fimmu.2023.1177324. eCollection 2023. Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice
Jana Beicht[SUP] 1 [/SUP], Mareike Kubinski[SUP] 1 [/SUP], Isabel Zdora[SUP] 2 3 [/SUP], Christina Puff[SUP] 2 [/SUP], Jeannine Biermann[SUP] 1 [/SUP], Thomas Gerlach[SUP] 1 [/SUP], Wolfgang Baumgärtner[SUP] 2 3 [/SUP], Gerd Sutter[SUP] 4 5 [/SUP], Albert D M E Osterhaus[SUP] 1 [/SUP], Chittappen Kandiyil Prajeeth[SUP] 1 [/SUP], Guus F Rimmelzwaan[SUP] 1 [/SUP]
Affiliations
Introduction: Tick-borne encephalitis virus (TBEV) is one of the most relevant tick-transmitted neurotropic arboviruses in Europe and Asia and the causative agent of tick-borne encephalitis (TBE). Annually more than 10,000 TBE cases are reported despite having vaccines available. In Europe, the vaccines FSME-IMMUN® and Encepur® based on formaldehyde-inactivated whole viruses are licensed. However, demanding vaccination schedules contribute to sub-optimal vaccination uptake and breakthrough infections have been reported repeatedly. Due to its immunogenic properties as well as its role in viral replication and disease pathogenesis, the non-structural protein 1 (NS1) of flaviviruses has become of interest for non-virion based flavivirus vaccine candidates in recent years.
Methods: Therefore, immunogenicity and protective efficacy of TBEV NS1 expressed by neuraminidase (NA)-deficient Influenza A virus (IAV) or Modified Vaccinia virus Ankara (MVA) vectors were investigated in this study.
Results: With these recombinant viral vectors TBEV NS1-specific antibody and T cell responses were induced. Upon heterologous prime/boost regimens partial protection against lethal TBEV challenge infection was afforded in mice.
Discussion: This supports the inclusion of NS1 as a vaccine component in next generation TBEV vaccines.
Keywords: IAV; MVA; NS1; T cells; TBEV; protection; vaccination; virus-neutralizing antibodies.
. 2023 Jul 7;14:1177324.
doi: 10.3389/fimmu.2023.1177324. eCollection 2023. Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice
Jana Beicht[SUP] 1 [/SUP], Mareike Kubinski[SUP] 1 [/SUP], Isabel Zdora[SUP] 2 3 [/SUP], Christina Puff[SUP] 2 [/SUP], Jeannine Biermann[SUP] 1 [/SUP], Thomas Gerlach[SUP] 1 [/SUP], Wolfgang Baumgärtner[SUP] 2 3 [/SUP], Gerd Sutter[SUP] 4 5 [/SUP], Albert D M E Osterhaus[SUP] 1 [/SUP], Chittappen Kandiyil Prajeeth[SUP] 1 [/SUP], Guus F Rimmelzwaan[SUP] 1 [/SUP]
Affiliations
- PMID: 37483628
- PMCID: PMC10360051
- DOI: 10.3389/fimmu.2023.1177324
Introduction: Tick-borne encephalitis virus (TBEV) is one of the most relevant tick-transmitted neurotropic arboviruses in Europe and Asia and the causative agent of tick-borne encephalitis (TBE). Annually more than 10,000 TBE cases are reported despite having vaccines available. In Europe, the vaccines FSME-IMMUN® and Encepur® based on formaldehyde-inactivated whole viruses are licensed. However, demanding vaccination schedules contribute to sub-optimal vaccination uptake and breakthrough infections have been reported repeatedly. Due to its immunogenic properties as well as its role in viral replication and disease pathogenesis, the non-structural protein 1 (NS1) of flaviviruses has become of interest for non-virion based flavivirus vaccine candidates in recent years.
Methods: Therefore, immunogenicity and protective efficacy of TBEV NS1 expressed by neuraminidase (NA)-deficient Influenza A virus (IAV) or Modified Vaccinia virus Ankara (MVA) vectors were investigated in this study.
Results: With these recombinant viral vectors TBEV NS1-specific antibody and T cell responses were induced. Upon heterologous prime/boost regimens partial protection against lethal TBEV challenge infection was afforded in mice.
Discussion: This supports the inclusion of NS1 as a vaccine component in next generation TBEV vaccines.
Keywords: IAV; MVA; NS1; T cells; TBEV; protection; vaccination; virus-neutralizing antibodies.